SCHEMBL1649673

SCHEMBL1649673

CCC1(O)C=COC=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15894639 0.78
SCHEMBL7162393 0.69
SCHEMBL6202960 0.62
SCHEMBL18211729 0.59
SCHEMBL28184226 0.57
SCHEMBL28922596 0.55
Ethylamine SCHEMBL8646820 0.54
SCHEMBL19167321 0.53
SCHEMBL729112 0.52
SCHEMBL20921304 0.52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115627629-A Antifouling processing method for fishing net rope by using hydroxy acid ester oligomer compound antifouling agent and product thereof 浙江英玛特生物科技有限公司 2023-01-20 CN claimed
CN-111837146-B G1T38 excellent dosing regimen G1治疗公司 2024-10-15 CN disclosed
CN-118234496-A Improved treatment of advanced/metastatic cancers with checkpoint inhibitor resistance or drug resistance susceptibility 海南先声再明医药股份有限公司 2024-06-21 CN disclosed
CN-118047687-A Compound for modifying 20 (S) camptothecin structure and synthesis method thereof 湖州澄博生物科技有限公司 2024-05-17 CN disclosed
CN-117562905-A Maintenance of immune response during chemotherapy regimen G1治疗公司 2024-02-20 CN disclosed
CN-117530948-A Maintenance of immune response during chemotherapy regimen G1治疗公司 2024-02-09 CN disclosed
CN-113406327-B Diagnosis and treatment of cancer involving cancer stem cells 生物技术公司 2023-10-31 CN disclosed
CN-116437913-A Pharmaceutical compounds for treating complement-mediated disorders 艾其林医药公司 2023-07-14 CN disclosed
CN-109172820-B Combination therapy involving antibodies directed against claudin 18.2 for the treatment of cancer 加尼梅德药物公司 2023-06-20 CN disclosed
CN-115989040-A Phospholipid-containing drug-clay mineral complex and orally administrable composition comprising same 韩国地质资源研究院 2023-04-18 CN disclosed
US-7927613-B2 Pharmaceutical co-crystal compositions UNIVERSITY OF SOUTH FLORIDA (US) 2011-04-19 US disclosed
US-20100297214-A1 PERCOLATIVE DRYING FOR THE PREPARATION OF PARTICLES MEDIGENE AG (DE) 2010-11-25 US disclosed
US-7790905-B2 Pharmaceutical propylene glycol solvate compositions MCNEIL-PPC, INC. (US) 2010-09-07 US disclosed
CN-101478968-A Camptothecin-analog with a novel, flipped lactone-stable, E-ring and methods for making and using same BIONUMERIK PHARMACEUTICALS INC (US) 2009-07-08 CN disclosed
EP-1915987-A1 Spray-freeze-drying process for the preparation of pellets comprising percolation drying MediGene AG (DE) 2008-04-30 EP disclosed
CN-101106995-A Pharmaceutical formulation for increasing solubility of 10-hydroxycamptothecin compounds in non-aqueous polar solvents SAMYANG CORP (KR) 2008-01-16 CN disclosed
CN-101007808-A Process for preparing superfine camptothecine UNIV BEIJING CHEMICAL (CN) 2007-08-01 CN disclosed
EP-0555347-A4 SUBSTITUTED INDOLIZINO 1,2-B)QUINOLINONES SMITHKLINE BEECHAM CORP (US) 1995-01-11 EP disclosed
EP-0555347-A1 SUBSTITUTED INDOLIZINO 1,2-b]QUINOLINONES SMITHKLINE BEECHAM CORPORATION (US) 1993-08-18 EP disclosed
WO-1992007856-A1 SUBSTITUTED INDOLIZINO[1,2-b]QUINOLINONES SMITHKLINE BEECHAM CORPORATION (US) 1992-05-14 WO disclosed